{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:53:51Z","timestamp":1766048031141},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1007\/s11914-996-0006-5","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:22:25Z","timestamp":1180131745000},"page":"116-122","source":"Crossref","is-referenced-by-count":6,"title":["Use of highly potent bisphosphonates in the treatment of osteoporosis"],"prefix":"10.1007","volume":"1","author":[{"given":"Michael","family":"McClung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"6_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel","year":"2001","unstructured":"NIH Consensus Development Panel: Osteoporosis prevention, diagnosis and treatment. JAMA 2001, 285:785\u2013795.","journal-title":"JAMA"},{"key":"6_CR2","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.1016\/0002-9343(91)90246-T","volume":"91","author":"AM Parfitt","year":"1991","unstructured":"Parfitt AM: Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med 1991, 91:42S-46S.","journal-title":"Am J Med"},{"key":"6_CR3","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Hausherr E, Chapuy MC, et al.: Markers of bone resorption predict hip fractures in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996, 11:1531\u20131538.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"6_CR4","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","volume":"9","author":"RG Russell","year":"1999","unstructured":"Russell RG, Croucher PI, Rogers MJ: Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999, 9(Suppl 2):S66-S80. A comprehensive review of bisphosphonate chemistry, pharmacology, and actions at the cellular and tissue levels.","journal-title":"Osteoporos Int"},{"key":"6_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623652","volume":"5","author":"JA Kanis","year":"1995","unstructured":"Kanis JA, Gertz BJ, Singer F, et al.: Rationale for the use of alendronate in osteoporosis. Osteoporos Int 1995, 5:1\u201313.","journal-title":"Osteoporos Int"},{"key":"6_CR6","doi-asserted-by":"crossref","unstructured":"Dufresne TE, Chmielewski PA, Manhart MD, et al.: Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 2003, Jul 11 [Epub ahead of print].","DOI":"10.1007\/s00223-002-2104-4"},{"key":"6_CR7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux PM, Arlot ME, Reda C, et al.: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 100:1475\u20131480.","journal-title":"J Clin Invest"},{"key":"6_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"CH Chesnut III","year":"1995","unstructured":"Chesnut CH III, McClung MR, Ensrud K, et al.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995, 99:144\u2013152.","journal-title":"Am J Med"},{"key":"6_CR9","first-page":"396","volume":"83","author":"L Mortensen","year":"1998","unstructured":"Mortensen L, Charles P, Bekker PJ, et al.: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998, 83:396\u2013402.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR10","first-page":"3109","volume":"85","author":"RP Tonino","year":"2000","unstructured":"Tonino RP, Meunier PJ, Emkey R, et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000, 85:3109\u20133115. This is the longest reported experience with potent bisphosphonate therapy. Stable inhibition of bone turnover persists with continued therapy. Indices of turnover remain well below baseline values for 2 years after discontinuing treatment.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","volume":"32","author":"OH Sorensen","year":"2003","unstructured":"Sorensen OH, Crawford GM, Mulder H, et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120\u2013126. This 5-year study is the longest placebo-controlled study with a potent bisphosphonate, demonstrating persistent anti-fracture effect during years 4 and 5 of treatment.","journal-title":"Bone"},{"key":"6_CR12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/jbmr.5650091003","volume":"9","author":"RP Heaney","year":"1994","unstructured":"Heaney RP: The bone remodeling transient: implications for the interpretation of clinical studies of bone mass changes. J Bone Miner Res 1994, 9:1515\u20131523.","journal-title":"J Bone Miner Res"},{"key":"6_CR13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687\u2013694.","journal-title":"Bone"},{"key":"6_CR14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, et al.: Meta-analyses of therapies for postmenopausal osteoporosis: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570\u2013578.","journal-title":"Endocr Rev"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(00)00301-X","volume":"27","author":"PD Delmas","year":"2000","unstructured":"Delmas PD: How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 2000, 27:1\u20133.","journal-title":"Bone"},{"key":"6_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","volume":"112","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002, 112:281\u2013289.","journal-title":"Am J Med"},{"key":"6_CR17","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003 18:1051\u20131056.","journal-title":"J Bone Miner Res"},{"key":"6_CR18","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437\u20131443.","journal-title":"N Engl J Med"},{"key":"6_CR19","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","volume":"17","author":"SL Greenspan","year":"2002","unstructured":"Greenspan SL, Bone G 3rd, Schnitzer TJ, et al.: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002, 17:1988\u20131996.","journal-title":"J Bone Miner Res"},{"key":"6_CR20","first-page":"711","volume":"101","author":"MM Luckey","year":"2003","unstructured":"Luckey MM, Gilchrist N, Bone HG, et al.: Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003, 101:711\u2013721.","journal-title":"Obstet Gynecol"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535\u20131541. This study first documented the effects of bisphosphonates on vertebral and nonvertebral fractures.","journal-title":"Lancet"},{"key":"6_CR22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson D, et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998, 280:2077\u20132082. Demonstrated influence of baseline BMD on nonvertebral fracture effectiveness of alendronate.","journal-title":"JAMA"},{"key":"6_CR23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"HA Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA, et al.: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999, 9:461\u2013468.","journal-title":"Osteoporos Int"},{"key":"6_CR24","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, et al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000, 85:4118\u20134124.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR25","first-page":"1492","volume":"85","author":"P Ravn","year":"2000","unstructured":"Ravn P, Weiss SR, Rodriguez-Portales JA, et al.: Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. J Clin Endocrinol Metab 2000, 85:1492\u20131497.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archinte.163.7.789","volume":"163","author":"BH Ascott-Evans","year":"2003","unstructured":"Ascott-Evans BH, Guanabens N, Kivinen S, et al.: Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med 2003, 163:789\u2013794.","journal-title":"Arch Intern Med"},{"key":"6_CR27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604\u2013610.","journal-title":"N Engl J Med"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebocontrolled extension trial. Arthritis Rheum 2001, 44:202\u2013211.","journal-title":"Arthritis Rheum"},{"key":"6_CR29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999, 282:1344\u20131352. First documentation of antifracture efficacy of risedronate.","journal-title":"JAMA"},{"key":"6_CR30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11:83\u201391. Confirmed the effectiveness of risedronate in a very high-risk population.","journal-title":"Osteoporos Int"},{"key":"6_CR31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, et al.: Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001, 344:333\u2013340. This is the first study to specifically evaluate the effectiveness of a bisphosphonate on hip fracture risk. A clear effect was demonstrated in women known to have osteoporosis. No effect was evident in very elderly women enrolled on the basis of fall-related risk factors.","journal-title":"N Engl J Med"},{"key":"6_CR32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, et al.: The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103\u2013111.","journal-title":"Calcif Tissue Int"},{"key":"6_CR33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"S Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277\u2013285.","journal-title":"Calcif Tissue Int"},{"key":"6_CR34","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","volume":"16","author":"BJ Riis","year":"2001","unstructured":"Riis BJ, Ise J, von Stein T, et al.: Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16:1871\u20131878.","journal-title":"J Bone Miner Res"},{"key":"6_CR35","unstructured":"Boniva FDA Drug Approval Package. 2003."},{"key":"6_CR36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1385\/JCD:5:2:143","volume":"5","author":"H Younes","year":"2002","unstructured":"Younes H, Farhat G, el-Hajj Fuleihan G: Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom 2002, 5:143\u2013149.","journal-title":"J Clin Densitom"},{"key":"6_CR37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00003495-200161060-00010","volume":"61","author":"SM Cheer","year":"2001","unstructured":"Cheer SM, Noble S: Zoledronic acid. Drugs 2001, 61:799\u2013805.","journal-title":"Drugs"},{"key":"6_CR38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653\u2013661.","journal-title":"N Engl J Med"},{"key":"6_CR39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, et al.: Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med 2000, 160:517\u2013525.","journal-title":"Arch Intern Med"},{"key":"6_CR40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"B Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H: Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003, 14:259\u2013262.","journal-title":"Osteoporos Int"},{"key":"6_CR41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s002230010036","volume":"69","author":"J Li","year":"2001","unstructured":"Li J, Mashiba T, Burr DB: Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001, 69:281\u2013286.","journal-title":"Calcif Tissue Int"},{"key":"6_CR42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE: Pamidronate and zoledronate induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115\u20131118.","journal-title":"J Oral Maxillofac Surg"},{"key":"6_CR43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/pmj.76.897.417","volume":"76","author":"AS Kashyap","year":"2000","unstructured":"Kashyap AS, Kashyap S: Hypoparathyroidism unmasked by alendronate. Postgrad Med J 2000, 76:417\u2013418.","journal-title":"Postgrad Med J"},{"key":"6_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, et al.: The acute phase response after bisphosphonate administration. Calcif Tissue Int 1987, 41:326\u2013331.","journal-title":"Calcif Tissue Int"},{"key":"6_CR45","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","volume":"86","author":"E Astrom","year":"2002","unstructured":"Astrom E, Soderhall S: Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002, 86:356\u2013364.","journal-title":"Arch Dis Child"},{"key":"6_CR46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, et al.: Bisphosphonateinduced osteopetrosis. N Engl J Med 2003, 349:457\u2013463.","journal-title":"N Engl J Med"},{"key":"6_CR47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00198-003-1426-z","volume":"14","author":"A Cohen","year":"2003","unstructured":"Cohen A, Shane E: Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 2003, 14:617\u2013630.","journal-title":"Osteoporos Int"},{"key":"6_CR48","first-page":"720","volume":"85","author":"HG Bone","year":"2000","unstructured":"Bone HG, Greenspan SL, McKeever C, et al.: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000, 85:720\u2013726.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR49","first-page":"1890","volume":"86","author":"ST Harris","year":"2001","unstructured":"Harris ST, Eriksen EF, Davidson M, et al.: Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001, 86:1890\u20131897.","journal-title":"J Clin Endocrinol Metab"},{"key":"6_CR50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al.: The effects of PTH and alendronate alone or in combination on bone mineral density and turnover in post-menopausal osteoporosis: 12 month results of the PTH and Alendronate (PaTH) Trial. N Engl J Med 2003, 349:1207\u20131215. This review demonstrated that the combination of parathyroid hormones and alendronate did not increase the BMD response compared with the parathyroid hormone alone.","journal-title":"N Engl J Med"},{"key":"6_CR51","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129\u20132134.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0006-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-996-0006-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0006-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:33:58Z","timestamp":1559435638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-996-0006-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s11914-996-0006-5","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}